INRIG JULA (Chief Medical Officer) sold 6.9% of their position (8.23K shares) of TRAVERE THERAPEUTICS, INC. on the open market
Open‑market sale worth $345.9K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 4/16/2026ACC: 0001902368-26-000005
Officer· Chief Medical Officer
Since Jan 2022
+5.77K
Net shares
Net buyer
$345.9K
Total sold
2
Open market trades
0B · 2S
3
Total transactions
14K acquired · 8.23K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
+14K
Price / share
—
Trade value
—
% of position
13.2%
4/13/2026
105.71K→119.71K
Common Stock
Direct
Shares
−7.21K
Price / share
$41.93
Trade value
$302.52K
% of position
6.0%
4/14/2026
119.71K→112.49K
Common Stock
Direct
Shares
−1.02K
Price / share
$42.61
Trade value
$43.38K
% of position
0.9%
4/15/2026
112.49K→111.47K
Total
Net shares
+5.77K
Net value
-$345.89K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/13/2026 | A · Award | +14K | — | — | 13.2% | 105.71K | 119.71K |
| Common Stock Direct | 4/14/2026 | S · Sale | −7.21K | $41.93 | $302.52K | 6.0% | 119.71K | 112.49K |
| Common Stock Direct | 4/15/2026 | S · Sale | −1.02K | $42.61 | $43.38K | 0.9% | 112.49K | 111.47K |
| Total | +5.77K | -$345.89K | ||||||
Derivative Transactions0
No derivative transactions reported